The majority (88%,

28 of 32) had minimal or moderate SB203580 solubility dmso activity (A1-A2), but 75% (24 of 32) showed fibrosis stage ≥ F2, of whom five had cirrhosis (Table 1). Group 4: Fifty-two samples were obtained 6 months to 5 years after stopping antiviral treatment from patients who achieved an SVR and were thus considered as complete responders (CR, Table 1). Fifty-three percent (24 of 45) were of genotype 1. Their serum HCV RNA was negative and their aminotransferase levels normal (Table 1). These CR patients exhibited similar degrees of liver disease (Metavir score) than the nonresponder (NR) patients (Table 1). The control group was composed of 17 normal human serum (NHS) samples from blood donors (negative for HCV, hepatitis B virus [HBV], and human immunodeficiency virus [HIV]). Where mentioned, sera were inactivated by heating to 56°C for 30 minutes before use. All serum samples had been stored at −80°C upon collection (INSERM

Unit 871 and/or Hepatogastroenterology Unit of Hôtel-Dieu Hospital, Lyon, France). HCV viral loads were quantified at the virology laboratory of the Hôtel-Dieu Hospital on the patient samples, using either the Versant HCV RNA 3.0 branched DNA assay from Bayer Selumetinib HealthCare (Tarrytown, NY) or the Quantiplex HCV RNA branched DNA assay from Chiron Corp. (Emeryville, CA), as specified by the manufacturer. All the results were converted and expressed in international units per milliliter of serum (1 MEq = 159,000 IU). HCV genotype was determined locally by the Line Probe Assay INNO-LiPA HCV II (Innogenetics, Ghent, Belgium). Three biotinylated peptides were synthesized: Peptide E1 (Bio-TFSPRRHWTTQGCNC-amide) covers aa residues 292-306 of the HCV E1 glycoprotein. Peptide E2A (Bio-PDQRPYCWHYPPKPC-amide) covers aa residues 480-494 and peptide E2B (Bio-LVDYPYRLWHYPCTI-amide) covers aa residues 608-622 of the HCV E2 glycoprotein.12 Peptides were dissolved in dimethyl sulfoxide (2.5% final), diluted with phosphate-buffered

saline (PBS) to 1 mg/mL, and stored at −20°C. Streptavidin MCE公司 (Promega) was coated onto 96-well Maxisorp microtiter plates (Immulon, Dynex) by incubating 100 μL (stock solution: 1 mg/mL diluted 1/100 in 0.1 M carbonate buffer [pH 9.6], i.e., 10 μg/mL in final) in each well (1 μg/well) overnight at 4°C. The wells were blocked with 200 μL of PBS 1× (Cambrex) containing 10% goat serum (Eurobio, CAECHV00) for 1 hour at 37°C. Plates were washed three times with PBS, and 100 μL of the biotinylated peptide solution (10 μg/mL) was added. For each sample, triplicate wells were coated with either peptide E1, E2A, or E2B for 2 hours at 37°C. After another wash with PBS, 100 μL of human serum diluted 1/250 or 1/500 in PBSTG (PBS containing 0.05% Tween 20 and 10% goat serum) was added to the wells and incubated for 2 hours at 37°C. The plates were washed four times with PBST, and conjugate was added.